Gensia Laboratories Ltd., a wholly owned subsidiary of GensiaPharmaceuticals Inc., said it has received FDA marketingapproval for intravenous sodium nitroprusside.
Sodium nitroprusside is a cardiovascular drug used toimmediately reduce blood pressure in hypertensive crises andfor producing controlled hypotension during anesthesia toreduce bleeding, according to the San Diego parent company(NASDAQ: GNSA).
The Irvine, Calif., subsidiary now has 16 approved abbreviatednew drug applications covering 12 generic drugs.
(c) 1997 American Health Consultants. All rights reserved.